McNicoll Lewis Vlak Maintains Buy on Spectrum Pharmaceuticals After Positive Zevalin Reports

McNicoll Lewis Vlak has published a research report on Spectrum Pharmaceuticals SPPI after the company reported positive results from Zevalin in the Journal 'Cancer'. In the report, MLV writes, "In several studies, we think Zevalin is beginning to demonstrate its potential for wide applicability across various sub-types of non-Hodgkin's lymphomas. In our view, positive results announced today in aggressive lymphomas could lead to indication expansion following initiation and completion with positive results of a registrational clinical trial in this setting. Moreover, these results could serve to further increase Zevalin's visibility and favorable opinion by hematologists and other high-prescribing physicians." McNicoll Lewis Vlak maintains its Buy rating and $25 price target on Spectrum Pharmaceuticals, which is currently trading up $0.38 from Friday's $15.23 closing price.